Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 6/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FGF1 | P05230 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22224176 | 0.90 | ALDH1A1 (0.43) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL13716367 | 0.87 | AMY2A (0.45) | LGALS8CA1CA2CA9TYR | |
| SCHEMBL16234072 | 0.87 | AMY2A (0.45) | LGALS8CA1CA2CA9TYR | |
| SCHEMBL26448835 | 0.87 | LGALS8 (0.46) | LGALS8ALDH1A1THRBCA1CA2 | |
| SCHEMBL23705114 | 0.84 | LGALS8 (0.51) | LGALS8L3MBTL1FGF1 | |
| SCHEMBL20027477 | 0.84 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL14690973 | 0.84 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL22098622 | 0.84 | LGALS8 (0.51) | LGALS8L3MBTL1FGF1 | |
| SCHEMBL10388284 | 0.84 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL24943577 | 0.84 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177029-A1 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | NOVO NORDISK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177029-A1 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | OGT, UGGT1, GALNT6 | LGALS8 263/4885ALDH1A1 1060/4885THRB 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.